Tatva Chintan Pharma Chem Receives SEBI Compliance Certificate for Q3 FY26
Tatva Chintan Pharma Chem Limited received a compliance certificate for the quarter ended December 31, 2025. The certificate from MUFG Intime India Private Limited confirms adherence to SEBI (Depositories and Participants) Regulations, 2018, regarding the processing of dematerialized securities.
This is a standard regulatory compliance update, confirming the company's adherence to SEBI regulations for the specified quarter. It does not introduce any new information that would significantly affect the company's operations or stock performance.
The announcement is a routine compliance filing regarding the processing of securities and does not contain any new financial information or strategic updates that would impact the sentiment.
Tatva Chintan Pharma Chem Limited has received a Compliance Certificate for the quarter ended December 31, 2025. This certificate, issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), the company's Registrar and Share Transfer Agent, confirms compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
The certificate confirms that securities received from depository participants for dematerialization during the quarter were processed and confirmed with the depositories. It also states that the securities were listed on the stock exchanges where they were previously listed. The registrar further confirmed that the received security certificates were mutilated and cancelled after verification, and the depositories' names were substituted in the register of members within the prescribed timelines.
This information will be uploaded to the company's website, www.tatvachintan.com.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.